2024 Greatest T1D Hits: A Glance at This Year’s Achievements
With the holiday season in full swing, we have many reasons to be thankful. While we look back on 2024,…
Results Are Out: Tzield Benefits Newly Diagnosed Individuals
A new study published in the New England Journal of Medicine shows Tzield can preserve beta cell health in certain…
Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
Targeting a New Hormone Helps to Prevent Type 1 Diabetes
A publication authored by Harvard University scientists has found that targeting a new hormone, FABP4, can enhance beta cell function…
First-in-Human T1D Vaccine Trial Reports Positive Results
A first-in-human study of the coxsackie B vaccine—made by Breakthrough T1D-funded researchers Drs. Hyoty and Knip—reports positive results.
Teplizumab (the Therapy that Delays T1D By Nearly 3 Years) Isn’t Approved…Yet
The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning…
Artificial Intelligence Identifies T1D Risk Factors in Children
Breakthrough T1D and IBM Research have published their first paper, applying world-class computing power to identify factors leading to the…
T1D Doesn’t Discriminate: Know Your Risk with T1Detect
How Breakthrough T1D’s screening education and awareness program can help address health disparities experienced by underserved members of the T1D…
FDA Advisory Committee Recommends that Teplizumab Receives Approval
An FDA Advisory Committee weighed the evidence, and the results were positive: They recommended that the FDA approve teplizumab for…
National DNA Day!
Aaron Michels, M.D., discovered that methyldopa—a therapy that has been used for 50 years to treat high blood pressure—may have…
